Drug
SRT2104 clinical trials
Also written SRT2104.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Name
Development codes
- SRT2104
- 10
Studies by the year they started
13 studies that test it; most in 2009 (6)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 6 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses SRT2104 is read from its arms, and is right about nine times in ten.
Testing it · 13
- Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human SubjectsCompletedPhase 2Sirtris, a GSK CompanyNCT00937326Written as SRT2104
- Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type PsoriasisCompletedPhase 2Sirtris, a GSK CompanyNCT01154101Written as SRT2104
- A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy VolunteersCompletedPhase 1Sirtris, a GSK CompanyNCT00938275Written as 0.5g SRT2104
- Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male VolunteersCompletedPhase 1GlaxoSmithKlineNCT00933062Written as SRT2104
- Clinical Study to Assess the Effects of SRT2104 and Prednisolone on Biomarkers in Blood in Healthy VolunteersCompletedPhase 1GlaxoSmithKlineNCT00920660Written as 0.25g SRT2104
- Effect of SRT2104 on Endotoxin-induced InflammationCompletedPhase 1GlaxoSmithKlineNCT01014117Written as SRT2104
- A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes MellitusCompletedPhase 1Sirtris, a GSK CompanyNCT01031108Written as SRT2104
- A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 DaysCompletedPhase 1GlaxoSmithKlineNCT00964340Written as SRT2104
- A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male SubjectsCompletedPhase 1Sirtris, a GSK CompanyNCT00937872Written as 250 mg SRT2104 Suspension
- A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative ColitisCompletedPhase 1Sirtris, a GSK CompanyNCT01453491Written as SRT2104
- A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male VolunteersCompletedPhase 1Sirtris, a GSK CompanyNCT00933530Written as SRT2104
- A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes MellitusCompletedPhase 2GlaxoSmithKlineNCT01018017Written as SRT2104
- A Clinical Study to Assess the Effects of SRT2104 Upon Immobilization-Induced Skeletal Muscle Atrophy in Healthy Human VolunteersWithdrawnPhase 1GlaxoSmithKlineNCT01039909Written as SRT2104